This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Anton Berns group

AntonBerns.jpg

Anton Berns

Sr.Group Leader

Personal details

Experience

Anton Berns studied biochemistry at the University of Nijmegen and received his Masters degree in 1969 (cum laude) and his PhD in 1972 (supervisor Prof. H. Bloemendal) from that same University (cum laude). He did his postdoctoral training in the group of Rudolf Jaenisch at the Salk Institute in La Jolla, CA., where he studied the role of retroviruses in causing lymphomas in mice. In 1976 he returned to the University of Nijmegen where he became junior staff member. His group explored proviral insertional mutagenesis as a means to identify new oncogenes. In 1985 he was appointed as staff scientist at the Netherlands Cancer Institute and in 1986 he became head of the Division of Molecular Genetics of the Institute. Here his group did pioneering work to generate and utilize genetically modified mice as a tool to search for new cancer genes. Currently, his group focuses on the development and use of advanced mouse models for cancer. Themes of his current research are: i. Development of tools to faster generate complex mouse models, ii. High throughput transposon insertional mutagenesis to identify components in signaling pathways relevant for cancer, and iii. The role of tumor heterogeneity and cells-of-origin of lung cancer and mesothelioma. His group consists of approximately 12 members including 4 technicians. In 1999, he was appointed as Director of Research and Chairman of the Board of Directors of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital from which he retired at the end of 2011. He continued his research a group leader in the Division of Molecular Genetics of the NKI.

Share this page